For example, one study showed that two years after undergoing genetic testing, CDKN2A carriers without a personal history of melanoma were found to have a 30% increase in adherence to total body skin examination (TBSEs) (p=0.032, one tailed) (60). Here, CDKN2A is linked to melanoma.